NeuroRx is planning to move NRX-101 into phase 2b/3 after detecting signs of efficacy in a feasibility trial in patients with suicidal bipolar depression. The small phase 2 feasibility study linked fixed-dose combination NRX-101 to improved scores on a depression rating scale.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,